Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

While colleges across the nation are adapting their curricula to harness the power of generative AI, U.S. medical schools remain dangerously behind.